禮來(LLY.US)非共價BTK抑制劑“匹妥布替尼“申報新適應症

智通財經

06-20

智通財經APP獲悉，6月18日，CDE網站顯示，禮來(LLY.US)的匹妥布替尼片劑申報新適應症。推測此次申報的適應症爲接受過至少兩種治療的慢性淋巴細胞白血病或小淋巴細胞淋巴瘤(CLL/SLL)成人患者。

匹妥布替尼(pirtobrutinib)是禮來研發的first-in-class非共價BTK C481S抑制劑。共價BTK抑制劑包括伊布替尼、澤布替尼、阿可替尼和奧布替尼，都是通過與BTK的C481殘基結合，阻斷ATP結合口袋，抑制BTK酶的活性從而發揮抗腫瘤作用，但C481突變會引起耐藥，而非共價抑制劑匹妥布替尼不依賴C481也可與BTK高選擇性結合，能夠克服C481突變導致的耐藥。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544719111"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544719111\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544719111?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-20 06:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544719111","market":"hk","top_or_hot":-1,"title":"禮來(LLY.US)非共價BTK抑制劑“匹妥布替尼“申報新適應症","media":"智通財經","content":"<html><body><p>智通財經APP獲悉，6月18日，CDE網站顯示，<a href=\"https://laohu8.com/S/LLY\">禮來</a>(LLY.US)的匹妥布替尼片劑申報新適應症。推測此次申報的適應症爲接受過至少兩種治療的慢性淋巴細胞白血病或小淋巴細胞淋巴瘤(CLL/SLL)成人患者。</p><p><img src=\"https://img.zhitongcaijing.com/image/20250620/1750372602999725.png\" title=\"1750372602999725.png\"/></p><p>匹妥布替尼(pirtobrutinib)是禮來研發的first-in-class非共價BTK C481S抑制劑。共價BTK抑制劑包括伊布替尼、澤布替尼、阿可替尼和奧布替尼，都是通過與BTK的C481殘基結合，阻斷ATP結合口袋，抑制BTK酶的活性從而發揮抗腫瘤作用，但C481突變會引起耐藥，而非共價抑制劑匹妥布替尼不依賴C481也可與BTK高選擇性結合，能夠克服C481突變導致的耐藥。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>禮來(LLY.US)非共價BTK抑制劑“匹妥布替尼“申報新適應症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n禮來(LLY.US)非共價BTK抑制劑“匹妥布替尼“申報新適應症\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-06-20 06:35</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP獲悉，6月18日，CDE網站顯示，<a href=\"https://laohu8.com/S/LLY\">禮來</a>(LLY.US)的匹妥布替尼片劑申報新適應症。推測此次申報的適應症爲接受過至少兩種治療的慢性淋巴細胞白血病或小淋巴細胞淋巴瘤(CLL/SLL)成人患者。</p><p><img src=\"https://img.zhitongcaijing.com/image/20250620/1750372602999725.png\" title=\"1750372602999725.png\"/></p><p>匹妥布替尼(pirtobrutinib)是禮來研發的first-in-class非共價BTK C481S抑制劑。共價BTK抑制劑包括伊布替尼、澤布替尼、阿可替尼和奧布替尼，都是通過與BTK的C481殘基結合，阻斷ATP結合口袋，抑制BTK酶的活性從而發揮抗腫瘤作用，但C481突變會引起耐藥，而非共價抑制劑匹妥布替尼不依賴C481也可與BTK高選擇性結合，能夠克服C481突變導致的耐藥。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1307504.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0006306889.USD","symbol_name":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1307504.html","article_id":"2544719111","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544719111","pubTimestamp":1750372544,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP獲悉，6月18日，CDE網站顯示，禮來(LLY.US)的匹妥布替尼片劑申報新適應症。推測此次申報的適應症為接受過至少兩種治療的慢性淋巴細胞白血病或小淋巴細胞淋巴瘤(CLL/SLL)成人患者。匹妥布替尼(pirtobrutinib)是禮來研發的first-in-class非共價BTK C481S抑制劑。共價BTK抑制劑包括伊布替尼、澤布替尼、阿可替尼和奧布替尼，都是通過與BTK的C481殘基結合，阻斷ATP結合口袋，抑制BTK酶的活性從而發揮抗腫瘤作用，但C481突變會引起耐藥，而非共價抑制劑匹妥布替尼不依賴C481也可與BTK高選擇性結合，能夠克服C481突變導致的耐藥。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","BK4588":"碎股","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LLY":"礼来","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","BK4007":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4585":"ETF&股票定投概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2063271972.USD":"富兰克林创新领域基金","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4516":"特朗普概念"},"translate_title":"Eli Lilly (LLY.US) non-covalent BTK inhibitor \"pitobrutinib\" declares new indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"智通財經APP獲悉，6月18日，CDE網站顯示，禮來(LLY.US)的匹妥布替尼片劑申報新適應症。推測此次申報的適應症為接受過至少兩種治療的慢性淋巴細胞白血病或小淋巴細胞淋巴瘤(CLL/SLL)成人患者。匹妥布替尼(pirtobrutinib)是禮來研發的first-in-class非共價BTK C481S抑制劑。共價BTK抑制劑包括伊布替尼、澤布替尼、阿可替尼和奧布替尼，都是通過與BTK的C481殘基結合，阻斷ATP結合口袋，抑制BTK酶的活性從而發揮抗腫瘤作用，但C481突變會引起耐藥，而非共價抑制劑匹妥布替尼不依賴C481也可與BTK高選擇性結合，能夠克服C481突變導致的耐藥。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}